Haris Riaz1, Safi U Khan2, Hammad Rahman3, Nishant P Shah1, Edo Kaluski4, A Michael Lincoff1, Steven E Nissen1. 1. 1 Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA. 2. 2 Department of Medicine, West Virginia University, Morgantown, WV, USA. 3. 3 Department of Medicine, Guthrie Health System/Robert Packer Hospital, Sayre, PA, USA. 4. 4 Department of Cardiovascular Medicine, Guthrie Health System/Robert Packer Hospital, Sayre, PA, USA.
Abstract
BACKGROUND: The effects of increasing high-density lipoprotein cholesterol on cardiovascular outcomes remain uncertain. DESIGN: We conducted a meta-analysis to investigate the effects of high-density lipoprotein cholesterol modifiers (niacin, fibrates and cholesteryl ester transfer protein inhibitors) on cardiovascular outcomes. METHODS: Thirty-one randomized controlled trials (154,601 patients) with a follow-up of 6 months or more and a sample size of 100 or more patients were selected using MEDLINE, EMBASE and CENTRAL database (inception January 2018). RESULTS: High-density lipoprotein cholesterol modifiers had no statistically significant effect on cardiovascular mortality in terms of relative risk (RR) (RR 0.94, 95% confidence interval (CI) 0.89-1.00, P = 0.05, I2 = 13%) or absolute risk (risk difference -0.0001, 95% CI -0.0014, 0.0011, P = 0.84, I2 = 28%). High-density lipoprotein cholesterol modifiers reduced the RR of myocardial infarction (RR 0.87, 95% CI 0.82-0.93, P < 0.001, I2 = 37%). This significant effect was derived by the use of fibrates (RR 0.80, 95% CI 0.73-0.87, P < 0.001, I2 = 22%) and meta-regression analysis showed that this benefit was consistent with an absolute reduction in low-density lipoprotein cholesterol. High-density lipoprotein cholesterol modifiers had no effect on stroke (RR 1.00, 95% CI 0.93-1.09, P = 0.94, I2 = 25%) or all-cause mortality (RR 1.02, 95% CI 0.97-1.08, P = 0.48, I2 = 49%). Meta-regression analyses failed to demonstrate a significant association of pharmacologically increased high-density lipoprotein cholesterol with key endpoints. In studies with background statin therapy, high-density lipoprotein cholesterol modifiers had no statistically significant impact on cardiovascular mortality, myocardial infarction, stroke or all-cause mortality ( P > 0.05). CONCLUSION: The use of high-density lipoprotein cholesterol modifying treatments had no significant effect on cardiovascular mortality, stroke or all-cause mortality. The beneficial effect on myocardial infarction was lost when drugs were used with statin therapy.
BACKGROUND: The effects of increasing high-density lipoprotein cholesterol on cardiovascular outcomes remain uncertain. DESIGN: We conducted a meta-analysis to investigate the effects of high-density lipoprotein cholesterol modifiers (niacin, fibrates and cholesteryl ester transfer protein inhibitors) on cardiovascular outcomes. METHODS: Thirty-one randomized controlled trials (154,601 patients) with a follow-up of 6 months or more and a sample size of 100 or more patients were selected using MEDLINE, EMBASE and CENTRAL database (inception January 2018). RESULTS: High-density lipoprotein cholesterol modifiers had no statistically significant effect on cardiovascular mortality in terms of relative risk (RR) (RR 0.94, 95% confidence interval (CI) 0.89-1.00, P = 0.05, I2 = 13%) or absolute risk (risk difference -0.0001, 95% CI -0.0014, 0.0011, P = 0.84, I2 = 28%). High-density lipoprotein cholesterol modifiers reduced the RR of myocardial infarction (RR 0.87, 95% CI 0.82-0.93, P < 0.001, I2 = 37%). This significant effect was derived by the use of fibrates (RR 0.80, 95% CI 0.73-0.87, P < 0.001, I2 = 22%) and meta-regression analysis showed that this benefit was consistent with an absolute reduction in low-density lipoprotein cholesterol. High-density lipoprotein cholesterol modifiers had no effect on stroke (RR 1.00, 95% CI 0.93-1.09, P = 0.94, I2 = 25%) or all-cause mortality (RR 1.02, 95% CI 0.97-1.08, P = 0.48, I2 = 49%). Meta-regression analyses failed to demonstrate a significant association of pharmacologically increased high-density lipoprotein cholesterol with key endpoints. In studies with background statin therapy, high-density lipoprotein cholesterol modifiers had no statistically significant impact on cardiovascular mortality, myocardial infarction, stroke or all-cause mortality ( P > 0.05). CONCLUSION: The use of high-density lipoprotein cholesterol modifying treatments had no significant effect on cardiovascular mortality, stroke or all-cause mortality. The beneficial effect on myocardial infarction was lost when drugs were used with statin therapy.
Authors: Safi U Khan; Muhammad U Khan; Haris Riaz; Shahul Valavoor; Di Zhao; Lauren Vaughan; Victor Okunrintemi; Irbaz Bin Riaz; Muhammad Shahzeb Khan; Edo Kaluski; M Hassan Murad; Michael J Blaha; Eliseo Guallar; Erin D Michos Journal: Ann Intern Med Date: 2019-07-09 Impact factor: 25.391
Authors: Wen Guo; Karol M Pencina; Jeremy D Furtado; Frank M Sacks; Tomas Vaisar; Ming Cheng; Allan D Sniderman; Stephanie T Page; Shalender Bhasin Journal: J Endocr Soc Date: 2022-06-28
Authors: Karol M Pencina; Arthur L Burnett; Thomas W Storer; Wen Guo; Zhuoying Li; Adam S Kibel; Grace Huang; Michelle Blouin; Donna L Berry; Shehzad Basaria; Shalender Bhasin Journal: J Clin Endocrinol Metab Date: 2021-07-13 Impact factor: 5.958
Authors: Safi U Khan; Muhammad Zia Khan; Charumathi Raghu Subramanian; Haris Riaz; Muhammad U Khan; Ahmad Naeem Lone; Muhammad Shahzeb Khan; Eve-Marie Benson; Mohamad Alkhouli; Michael J Blaha; Roger S Blumenthal; Martha Gulati; Erin D Michos Journal: JAMA Netw Open Date: 2020-05-01